Results 31 to 40 of about 5,967 (167)

Molecular characterization of cancers with NTRK gene fusions [PDF]

Modern Pathology, 2019
Targeted inhibitors of neurotropic tyrosine kinases are highly effective in selected patients with gene fusions involving NTRK1, NTRK2, or NTRK3. These fusions are consistently detected in rare cancer types (e.g., secretory breast carcinoma and congenital infantile fibrosarcoma), but the occurrence of NTRK fusions in common cancers and their ...
Zoran Gatalica, Joanne Xiu, Jeffrey Swensen, Semir Vranic   +3 more
openaire   +4 more sources

NTRK Somatic Fusions and Tumor Agnostic Treatment in Pediatric Cancers

Journal of Contemporary Medicine, 2022
Neurotrophic tyrosine receptor kinase (NTRK) gene rearrangements have been recently identified and developed as one of the biomarkers that have been utilized as new targets for cancer therapy.
Emel Ünal, Sonay İncesoy Özdemir, Ayça Yağmur Şimşek   +2 more
doaj   +1 more source

Identification of Trim24 as a new NTRK3 fusion partner in lung adenocarcinoma: Diagnostic challenges of a novel fusion

Human Pathology Reports, 2022
Reliable neurotrophin kinase (NTRK) fusion assessment is of special relevance since durable responses to targeted therapies have been observed regardless tumor type, NTRK gene or fusion partner.
Almudena Santón, Eugenia Olmedo, Tamara Caniego-Casas, Amparo Benito, Mónica García-Cosío, Jorge Esteban-Villarrubia, Pilar Garrido, José Palacios   +7 more
doaj   +1 more source

EML4–NTRK3 Fusion Cervical Sarcoma: A Case Report and Literature Review

Frontiers in Medicine, 2022
The concept of neurotrophic factor tyrosine kinase receptor (NTRK) fusion tumor has emerged in recent years. Moreover, NTRK fusion is unusual in common tumors but can often be identified in rare tumors.
Xiaohe Dang, Tao Xiang, Can Zhao, Hao Tang, Pengfei Cui   +4 more
doaj   +1 more source

Case Report: Identification of a novel NTRK3-AJUBA fusion co-existing with ETV6-NTRK3 fusion in papillary thyroid carcinoma

Frontiers in Oncology, 2023
NTRK fusions are validated oncogenic drivers of various adult and pediatric tumor types, including thyroid cancer, and serve as a therapeutic target. Recently, tropomyosin receptor kinase (TRK) inhibitors, such as entrectinib and larotrectinib, display ...
Qing-Xiang Yu, Wen-Jun Zhao, He-Yue Wang, Lei Zhang, Lan Qin, Lei Zhang, Jian-li Han   +6 more
doaj   +1 more source

Safety of current treatment options for NTRK fusion-positive cancers. [PDF]

Expert Opin Drug Saf, 2023
Oncogenic NTRK fusions have been found in multiple cancer types affecting adults and/or children, including rare tumors with pathognomonic fusions and common cancers in which fusions are rare. The tropomyosin receptor kinase inhibitors (TRKi) larotrectinib and entrectinib are among the first agents with tissue agnostic FDA approvals for cancer ...
Yang AT, Laetsch TW.
europepmc   +3 more sources

NTRK fusions in osteosarcoma are rare and non‐functional events [PDF]

The Journal of Pathology: Clinical Research, 2020
AbstractNeurotrophic tyrosine receptor kinase (NTRK) fusions are promising molecular targets that have been described in a broad range of malignant tumours. Fusions commonly lead to the expression of chimeric proteins with constitutive tyrosine kinase activation that drives tumorigenesis.
Baptiste Ameline, Karim H Saba, Michal Kovac, Linda Magnusson, Olaf Witt, Stefan Bielack, Michaela Nathrath, Karolin H Nord, Daniel Baumhoer   +8 more
openaire   +4 more sources

A systematic review and meta-analysis of neurotrophic tyrosine receptor kinase gene fusion frequencies in solid tumors

Therapeutic Advances in Medical Oncology, 2020
Introduction: The research objective was to systematically review evidence on neurotrophic tyrosine receptor kinase ( NTRK ) gene fusion frequency in solid tumors. Methods: Using Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)
Anna Forsythe, Wei Zhang, Uwe Phillip Strauss, Marc Fellous, Maesumeh Korei, Karen Keating   +5 more
doaj   +1 more source

Detection of NTRK fusions by RNA-based nCounter is a feasible diagnostic methodology in a real-world scenario for non-small cell lung cancer assessment

Scientific Reports, 2023
NTRK1, 2, and 3 fusions are important therapeutic targets for NSCLC patients, but their prevalence in South American admixed populations needs to be better explored.
Rodrigo de Oliveira Cavagna, Edilene Santos de Andrade, Monise Tadin Reis, Flávia Escremim de Paula, Gustavo Noriz Berardinelli, Murilo Bonatelli, Gustavo Ramos Teixeira, Beatriz Garbe Zaniolo, Josiane Mourão Dias, Flávio Augusto Ferreira da Silva, Carlos Eduardo Baston Silva, Marina Xavier Reis, Erika Lopes Maia, Thainara Santos de Alencar, Alexandre Arthur Jacinto, Rachid Eduardo Noleto da Nóbrega Oliveira, Miguel A. Molina-Vila, Letícia Ferro Leal, Rui Manuel Reis   +18 more
doaj   +1 more source

Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults

Current Oncology, 2021
The tyrosine receptor kinase (TRK) inhibitors larotrectinib and entrectinib were recently approved in Canada for the treatment of solid tumours harbouring neurotrophic tyrosine receptor kinase (NTRK) gene fusions.
D. Gwyn Bebb, Shantanu Banerji, Normand Blais, Patrice Desmeules, Sharlene Gill, Andrea Grin, Harriet Feilotter, Aaron R. Hansen, Martin Hyrcza, Monika Krzyzanowska, Barbara Melosky, Jonathan Noujaim, Bibiana Purgina, Dean Ruether, Christine E. Simmons, Denis Soulieres, Emina Emilia Torlakovic, Ming-Sound Tsao   +17 more
doaj   +1 more source